AIM
NGNE icon

Acrospire Investment Management’s Neurogene NGNE Stock Holding History

Acrospire Investment Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-116
Closed -$38K – 2399
2016
Q4 		$38K Buy
+116
New +$31.2K 0.02% 1532

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Acrospire Investment Management's NGNE Position: Q1 2017 in Review

Acrospire Investment Management sold out of Neurogene (NGNE) in Q1 2017, closing a stake of 116 shares — an estimated $38K sold.

Acrospire Investment Management first reported a position in NGNE in Q4 2016 and held it in 1 quarter. The position peaked at $38K in Q4 2016. 39 funds tracked by Wall St. Rank hold NGNE as of Q1 2017.

  • Acrospire Investment Management reported no remaining Neurogene position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 116 Neurogene shares in Q1 2017, an estimated $38K.
  • Acrospire Investment Management first reported a position in Neurogene in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Neurogene position peaked at $38K in Q4 2016.
  • 39 funds tracked by Wall St. Rank held Neurogene as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.